Traws Pharma Management
Management criteria checks 1/4
Traws Pharma's CEO is Iain Dukes, appointed in Mar 2025, has a tenure of 1.17 years. total yearly compensation is $1.40M, comprised of 38.4% salary and 61.6% bonuses, including company stock and options. directly owns 0.53% of the company’s shares, worth $119.97K. The average tenure of the management team and the board of directors is 2.1 years and 2.1 years respectively.
Key information
Iain Dukes
Chief executive officer
US$1.4m
Total compensation
| CEO salary percentage | 38.45% |
| CEO tenure | 1.2yrs |
| CEO ownership | 0.5% |
| Management average tenure | 2.1yrs |
| Board average tenure | 2.1yrs |
Recent management updates
Recent updates
Pandemic Preparedness And Once Monthly Oral Flu Prophylaxis Will Transform This Antiviral Opportunity
Catalysts About Traws Pharma Traws Pharma is a biotechnology company focused on developing next generation antiviral treatments and prophylactic agents for influenza. What are the underlying business or industry changes driving this perspective?
Regulatory And Funding Risks Around Influenza Catalyst Will Eventually Support A Healthier Outlook
Catalysts About Traws Pharma Traws Pharma is a clinical stage company focused on developing next generation antiviral treatments and prophylactic therapies for influenza. What are the underlying business or industry changes driving this perspective?We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Will Onconova Therapeutics (NASDAQ:ONTX) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Companies Like Onconova Therapeutics (NASDAQ:ONTX) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$14m |
| Dec 31 2025 | US$1m | US$539k | US$7m |
Compensation vs Market: Iain's total compensation ($USD1.40M) is above average for companies of similar size in the US market ($USD626.93K).
Compensation vs Earnings: Insufficient data to compare Iain's compensation with company performance.
CEO
Iain Dukes (67 yo)
Dr. Iain D. Dukes, M.A. D.Phil. & Ph D., is the Chairman, Chief Business Officer & Executive Director of Brenig Therapeutics, Inc. Dr. Dukes is a Director of NeRRe Therapeutics Ltd. Dr. Iain D. Dukes serve...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Secretary & Director | 1.2yrs | US$1.40m | 0.53% $ 120.0k | |
| COO & Director | 2.1yrs | US$734.81k | 0.53% $ 120.0k | |
| Chief Scientific Officer of Virology | 2.1yrs | US$1.01m | 0% $ 0 | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Medical Officer of Oncology | 2.8yrs | US$478.44k | 0% $ 0 | |
| Chief Medical Officer | 2.1yrs | no data | 0.16% $ 36.3k |
Experienced Management: TRAW's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Secretary & Director | 2.1yrs | US$1.40m | 0.53% $ 120.0k | |
| COO & Director | 2.1yrs | US$734.81k | 0.53% $ 120.0k | |
| Director | 2.1yrs | US$353.18k | 0.64% $ 143.6k | |
| Independent Chairman | 10yrs | US$340.89k | 0% $ 0 | |
| Independent Director | less than a year | US$87.73k | no data | |
| Independent Director | 6.1yrs | US$215.89k | 0% $ 0 | |
| Independent Director | 3.4yrs | US$213.89k | 0% $ 0 |
Experienced Board: TRAW's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/26 15:05 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Traws Pharma, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kimberly Lee | Brean Capital Historical (Janney Montgomery) |
| Michael Thomas Cooper | Edison Investment Research |
| Etzer Darout | Guggenheim Securities, LLC |